The Association for the Accreditation of Human Research Protection Programs Inc
. (AAHRPP) today announced that it has awarded accreditation to five more organizations, including the first institution in Latin America.
The latest accreditations are yet another example of AAHRPP’s continued expansion and influence in the United States and emerging markets. The newly accredited organizations are:
Latin American countries are playing an increased role in clinical research. Mexico, in particular, is emerging as a leading clinical research location because of its proximity to the United States. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán is one of 12 National Institutes of Health in Mexico and is the among the country’s largest centers for medical training and research.
According to AAHRPP President and CEO Marjorie Speers, Ph.D., AAHRPP’s continued outreach worldwide reflects a longstanding commitment to protect participants and advance quality research both within and beyond the U.S.
“From the beginning, we recognized the global nature of the research enterprise,” Speers said. “We knew that accrediting U.S. institutions was critical and that it would be the first step toward a more ambitious goal of achieving one standard worldwide—for research quality and protections.”
To earn AAHRPP accreditation, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiránhad to demonstrate compliance with both Mexico’s requirements for research protections and U.S. regulations.
The four new U.S. accreditations reflect widespread acknowledgement that AAHRPP accreditation is the mark of a high-quality research protection program.
“Organizations of every size and sector of the research enterprise see the value of AAHRPP accreditation—the emphasis on quality and protections and the resulting respect of sponsors and peers,” Speers says.
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Korea, Mexico, Singapore and Taiwan.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.